This inventor holds 1 USPTO granted patent, plus 1 CIPO patent. Top assignee: Oncotherapy Science, Incorporated. Active years: 2021.
Company Filing History:
Years Active: 2021
Title: Suyoun Chung: Innovator in Monoclonal Antibody Research
Introduction
Suyoun Chung is a prominent inventor based in Kawasaki, Japan. She has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. Her work focuses on innovative solutions for diagnosing and treating diseases associated with MELK.
Latest Patents
Suyoun Chung holds a patent titled "Monoclonal antibody against MELK and utilization thereof." This invention relates to monoclonal antibodies that target MELK, a protein implicated in various diseases. The patent outlines methods for diagnosing MELK-associated diseases, detecting the MELK protein, and determining drug efficacy following treatment with a MELK inhibitor. Additionally, it includes methods for screening subjects who may benefit from MELK inhibitors and diagnostic reagents containing the antibodies. She has 1 patent to her name.
Career Highlights
Suyoun Chung is currently employed at Oncotherapy Science, Incorporated, where she continues her research and development efforts. Her work is instrumental in advancing therapeutic options for patients suffering from MELK-related conditions.
Collaborations
Suyoun Chung collaborates with notable colleagues in her field, including Yusuke Nakamura and Yosuke Harada. Their combined expertise enhances the research and development processes at Oncotherapy Science.
Conclusion
Suyoun Chung is a trailblazer in the field of monoclonal antibody research, with her innovative patent contributing to advancements in medical diagnostics and treatment. Her dedication to improving healthcare through scientific innovation is commendable.